comprehensive -WSS

comprehensive

author：fashion 2025-08-12 09:13:18 - browse：69295

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

WSS

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

FTC loses bid to block Novant's North Carolina hospital merger

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Poor hospice wound care hurts patients and families

entertainment

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sutter Health’s antitrust win overturned by appeals court

At least 13 dead in Texas as scorching temps continue

FDA's Woodcock to retire early next year

Anesthesiologist group: stop taking Ozempic before surgery

Does good food count as health care? Study aims to find out

Bright Health sells Medicare Advantage business to Molina

NYU radiologists take on the challenge of expensive MRI machines

The high cost of giving birth even with insurance

ASCO Takeaways: Winners, snoozers, and the art of cancer care

entertainment

NYU radiologists take on the challenge of expensive MRI machines

Gain of function research would be limited under House proposal

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

A new initiative will help leaders fight the next pandemic

leisure time

knowledge

knowledge

leisure time